Although approaches to target cell surface nucleolin in cancer have been developed [35, 50], dPSA and the dPSA biosynthetic pathway have potential advantages for the development of cancer diagnostics and therapeutics. The gene discussed is NUCLEOLIN; the disease is cancer.